Savara Pharmaceuticals

Summary
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

History

Savara was founded in 2008 by clinical-stage, specialty pharmaceutical companies focused on the development and commercialization of innovative therapies for rare respiratory diseases. The company has raised over $100 million in venture capital and has multiple products in clinical development. In 2012, Savara entered into an exclusive licensing agreement with Alexion Pharmaceuticals, to develop and commercialize their drug, Aravive, for the treatment of idiopathic pulmonary fibrosis.


Mission
To develop innovative therapies that make a meaningful difference in the lives of patients suffering from serious and life-threatening rare respiratory diseases.

Vision
To be the leader in the development and commercialization of breakthrough therapies for the treatment of serious and life-threatening rare respiratory diseases.

Key Team

Ms. Anne Erickson (Sr. VP & Head of Global Bus. Operations)

Brian Maurer (Head of Clinical Operations)

Mr. Charles LaPree (Sr. VP of Global Regulatory Affairs & Quality Assurance)

Dr. Peter Clarke Ph.D. (Exec. VP of Global Technical Operations)

Dr. Raymond Dennis Pratt FACP, M.D. (Chief Medical Officer)


Recognition and Awards
In 2017, Savara was recognized as 'Top 10 Company in Inhalation & Respiratory Drug Delivery.' In 2015, Savara was named one of the 'Top 25 Most Promising Companies to Watch' by the drug delivery industry journal, PharmaVOICE.

References
Savara Pharmaceuticals
Leadership team

Mr. Matthew Pauls (Chairman & CEO)

Mr. David L. Lowrance CPA (CFO & Sec.)

Ms. Kate McCabe (Sr. VP of Legal Affairs)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical
Headquarters
Austin, Texas, United States
Established
2007
Company Registration
SEC CIK number: 0001160308
Traded as
SVRA
Social Media
Wed Feb 28 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium